Neurocrine Biosciences Inc NBIX:NASDAQ

Last Price$75.10NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$72.00 (10)
Ask (Size)$75.10 (61)
Day Low / HighN/A - N/A
Volume1.2 M
  • Latest Stories
  • Commentary and Analysis
Barclays Adjusts Neurocrine Biosciences Price Target to $100 From $110, Maintains Overweight Rating
12:20PM ET 1/20/2022 MT Newswires

Neurocrine Biosciences (NBIX) has an average rating of Outperform and price targets ranging from $76 to $154, according to analysts polled by Capital IQ....

Neurocrine Biosciences Shares Drop After RBC Downgrade
2:27PM ET 1/18/2022 MT Newswires

Neurocrine Biosciences (NBIX) shares were down 4% in Tuesday afternoon trading after RBC downgraded the biopharmaceutical company's stock to sector perform...

RBC Downgrades Neurocrine Biosciences to Sector Perform From Outperform, Sees 2022 as 'Investment Year' With Fewer Upside Catalysts, Cuts Price Target to $90 From $122
8:58AM ET 1/18/2022 MT Newswires

Neurocrine Biosciences (NBIX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $76 to...

Xenon Pharmaceuticals Says Partner Neurocrine Biosciences Hits Regulatory Milestone in Epilepsy Collaboration
9:01AM ET 1/12/2022 MT Newswires

Xenon Pharmaceuticals (XENE) said Wednesday said it was set to receive a payment of $15 million from its epilepsy joint venture partner Neurocrine...

RBC Capital Trims Neurocrine Biosciences' Price Target to $122 From $125 'on Ingrezza Sales Adjustments;' Outperform Rating Kept
9:36AM ET 1/07/2022 MT Newswires

Neurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $76 to $154, according to analysts polled by Capital IQ....

Neurocrine Biosciences Preliminary Ingrezza Sales Up 25% in Q4'21
4:28PM ET 1/06/2022 MT Newswires

Neurocrine Biosciences (NBIX) on Thursday reported preliminary Ingrezza drug sales of about $301 million for Q4 and about $1.1 billion for the full year...

RBC Raises Price Target on Neurocrine Biosciences to $125 From $122, Maintains Outperform Rating
8:09AM ET 1/06/2022 MT Newswires

Neurocrine Biosciences (NBIX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $76 to...

Oppenheimer Adjusts Neurocrine Biosciences PT to $154 From $140, Maintains Outperform Rating
12:11PM ET 12/08/2021 MT Newswires

Neurocrine Biosciences (NBIX) has an average rating of Outperform and price targets ranging from $76 to $154, according to analysts polled by Capital IQ....

Neurocrine Biosciences' Positive Huntington Disease Results Should Help Add $300 Million to Drug Sales, RBC Says
11:38AM ET 12/08/2021 MT Newswires

Neurocrine Biosciences' (NBIX) positive results from a late-stage study of its experimental Ingrezza valbenazine drug in adults with chorea tied to...

Citigroup Adjusts Price Target on Neurocrine Biosciences to $129 From $127, Maintains Buy Rating
9:22AM ET 12/08/2021 MT Newswires

Neurocrine Biosciences (NBIX) has an average outperform rating and a price target range of $76 to $154, according to analysts polled by Capital IQ. (MT...